Opportunity overview
LSL/MED/0246 Procurement description Provide sufficient information to understand the scope of the procurement. In April 2015 the MOD signed a thirteen year contract with Leidos Europe Ltd to provide the procurement and inventory management of commodity items (as well as the storage and distribution services) historically provided in-house by the Logistic Commodities and Services Operating Centre. Leidos, working with the MOD, will transform the way these services are delivered to ensure requirements continue to be met whilst providing best value for money for the department. The organisation delivering these services is known as Team Leidos. Team Leidos would like to make markets aware that we are intending to investigate innovative approaches to fill our Supply of Tranexamic Acid Auto-Injector (TXA AI) requirements. We are actively seeking innovative, commercially viable solutions to meet this critical requirement. We invite industry partners to engage with us and bring forward novel approaches that can accelerate delivery, enhance operational effectiveness, and meet the evolving needs of Defence. We are interested in an Auto-Injector device containing 1g of Tranexamic Acid (TXA) in no greater than 3ml volume. It is the aim of this Preliminary Market Engagement Notice (PMEN) to encourage companies, suppliers, or manufacturers to make us aware and provide as much information as they are comfortable with, to help decide the future strategy for the range. Team Leidos wishes to generate interest, information and views with other companies to understand the current market innovation and gain useful intelligence that can help our requirement. To request the PMEN documents please contact: Name and Email address Christina.brice103@teamleidos.mod.uk In the email request the documents related the Supply of Tranexamic Acid Auto-Injector (TXA AI). The documents will then be sent for completion and should be returned to the same email addresses before the deadline. Responses are required as soon as possible to inform next steps, but the PMEN will remain open until 27/07/2026 The value of this framework is estimated to be between £4,000,000 - £5,000,000
Classification
- CPV33600000 — Pharmaceutical products
- CPV33690000 — Various medicinal products
- CPV33692500 — Injectable solutions
Lots
- Lot 1Value not stated
Documents and notices
- Preliminary market engagement notice on Find a TenderOpen source ↗